Mineralys Reports Pivotal BP Trial Wins and $200M Tanabe License Amendment
MLYS sits 95% above its 52-week low of $13.4.
Summary
Mineralys reported pivotal Phase 3 and Phase 2 wins showing durable systolic blood pressure drops for lorundrostat, with an open-label extension underway. The company also amended its Tanabe license, paying $200M upfront to remove royalties, with up to $355M in milestone payments tied to commercialization. CMO Dr. Terry Ferguson received equity awards on Aug 10. This follows the June 3 IP buyout and $150M offering; the trial data strengthens the case ahead of the December 2026 FDA decision.
At the time of this announcement, MLYS was trading at $26.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $13.40 to $47.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.